People with small cell lung cancer (SCLC) treated with the immune-based cancer therapy atezolizumab are at an increased risk of developing Lambert-Eaton myasthenic syndrome (LEMS), according to a database analysis of adverse events. The analysis was detailed in a study, “Increased risk of Lambert-Eaton myasthenic syndrome (LEMS)…
Lambert-Eaton myasthenic syndrome (LEMS) arose in association with a rare type of aggressive skin cancer called Merkel cell carcinoma (MCC), a case study reported for the first time. The patient was successfully treated with a combination of radiotherapy, chemotherapy, and immunotherapy, which may be a suitable strategy for those…
Muscle responses to low-frequency repetitive nerve stimulation in people with Lambert-Eaton myasthenic syndrome (LEMS) were different from those of patients with myasthenia gravis (MG), a study reported. Because LEMS and MG are both autoimmune diseases marked by muscle weakness and other overlapping symptoms, this test may help distinguish…
Plasma exchange therapy eased the symptoms of a man with Lambert-Eaton myasthenic syndrome (LEMS) who tested negative for disease-related autoantibodies, according to a case series study. Researchers noted that a diagnosis of LEMS often relies on the presence of autoantibodies — immune proteins that mistakenly target a…
A rare case of Lambert-Eaton myasthenic syndrome (LEMS) triggered by an immune-related cancer therapy was recently described in a case study. Because immunotherapy is relatively new, patients receiving these treatments should be monitored for “unexpected and unknown side effects,” the researchers noted. The case study, “Lambert-Eaton…
Catalyst Pharmaceuticals has announced its partner DyDo Pharma has launched a Phase 3 registrational trial in Japan to evaluate the safety and effectiveness of Firdapse (amifampridine) to treat Lambert-Eaton myasthenic syndrome (LEMS). A registrational trial is designed to obtain sufficient clinical data to support the filing…
Firdapse (amifampridine) improved muscle strength and response to nerve cell stimulation in adults with Lambert-Eaton myasthenic syndrome (LEMS), a pooled analysis of six clinical trials demonstrated. The findings showed that all six previous trials together “showed significant efficacy, consistent with earlier reports of beneficial efficacy” of Firdapse —…
Almost all people with Lambert-Eaton myasthenic syndrome (LEMS) have generalized symptoms at disease onset, according to an analysis of data from a Dutch patient registry. That finding, and others, were similar between patient-completed questionnaires and medical records, which supported…
The molecule 3,4-diaminopyridine (3,4-DAP) — approved as Firdapse and Ruzurgi to treat people with Lambert-Eaton myasthenic syndrome (LEMS) — works to directly induce the release of chemical messengers by binding to potassium channels, without affecting calcium channels as previously thought, a study reported. …
Get regular updates to your inbox.